Hydroxychloroquine in diabetic kidney disease

Effect of hydroxychloroquine on progression of diabetic kidney disease in type 2 diabetes mellitus patients: An open labelled randomized controlled trial (pilot study) - NIL

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064921

Enrollment

100

Registered

2024-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Standard medical therapy along with Tab Hydroxychloroquine 400 mg once daily for 6 months: Participants in the study will be divided into two groups. Intervention group will receive app

Eligibility

Inclusion criteria

Inclusion criteria: all patients more than 18 years of age with diagnose type 2 diabetes mellitus and eGFR 45-90 ml/minute/1.73 sqm and macroalbuminuria

Exclusion criteria

Exclusion criteria: renal artery stenosis, end stage renal disease, critical illness, retinal maculopathy, known hypersensistivity to drug, prolonged QT interval, pregnants and lactating females

Design outcomes

Primary

Measure	Time frame
Change in urine albumin creatinine ratio, Change in duration for doubling of serum creatinine, Effect on eGFR Timepoint: Primary outcomes will be assessed at 3 months and 6 months from baseline	—

Secondary

Measure	Time frame
Change in IL-6 from baseline, change in hsCRP from baseline, change in dose of anti-diabetic drugs, change in dose of anti-hypertensives.Timepoint: Secondary outcomes will be assessed at 3 months & 6 months from baseline	—

Countries

India

Contacts

Public ContactDr. Deepak Thiriveedi

Jawaharlal Nehru Medical College, KLE University

manjunath.r.goroshi@gmail.com9930270424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026